Individual Study / TOMaaT

Transfusie Op Maat (Patient Blood Management )

Transfusie Op Maat (Patient Blood Management )

Initiatives -
To investigate whether the use of alternatives to allogeneic blood for patients undergoing elective total knee or hip replacement surgery, e.g. the infusion of erythropoietin, the use of the cell-saver or the reinfusion of autologous wound drained blood, can lead to continuous sparing of allogeneic blood if a restrictive transfusion policy is used. The effect on post-operative complications, length of hospital stay, mobilization and rehabilitation, and the quality of life in relation to the estimated cost will also be investigated. *Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*
Start Year
End Year
grant PPOC-03-002 from Sanquin Blood Supply (Amsterdam, The Netherlands) and by grant 06-601 from ZonMW (The Hague, The Nether-lands). In addition, Roche (Roche Nederland BV, Woerden, The Netherlands) and Haemonetics (Breda, The Nether-lands) provided grants for laboratory analyses (cytokine analyses) of wound blood (not reported in this study).
Visit TOMaaT


Investigators Contacts
  • Dr. Cynthia So-Osman
    Sanquin Blood Supply
  • Dr. Prof. Rob Nelissen
    Leiden University Medical Center


Study design
Clinical trial cohort

Marker Paper

So-Osman C, Nelissen RG, Koopman-van Gemert AW, Kluyver E, Pöll RG, Onstenk R, Van Hilten JA, Jansen-Werkhoven TM, van den Hout WB, Brand R, Brand A. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology. 2014 Apr;120(4):839-51. doi: 10.1097/ALN.0000000000000134.

PUBMED 24424070


Sources of Recruitment
  • Individuals

Number of participants

Number of participants
Number of participants with biosamples
Supplementary Information
Orthopedic patients of 18 years and older being considered for a total knee replacement (TKR), total hip replacement (THR) or TKR/THR revision.


Availability of data and biosamples